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Background
In human cancers, loss of PTEN, stabilization of hypoxia
inducible factor-1a, and activation of Ras and AKT con-
verge to increase the activity of a regulator of glycolysis,
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase
(PFKFB3). This enzyme synthesizes fructose-2,6-bispho-
sphate (F2,6BP), which is an activator of 6-phosphofructo-
1-kinase, a key step of glycolysis that is tightly controlled
by multiple metabolic feedback mechanisms. We recently
identified the first competitive small molecule inhibitor of
PFKFB3, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one
(3PO), and have now sought to develop a more potent
PFKFB3 inhibitor with improved PK properties for testing
in clinical trials.
Materials and methods
Methods included recombinant PFKFB3 assays, PK studies
using mass spectrometry, pre-clinical toxicity and efficacy
studies, Western blot analyses for HIF-1a and PFKFB3 in
A375 melanoma cells, F2,6BP assessments and flow cyto-
metry for apoptosis.
Results
We report the discovery of a novel 3PO-derivative,
PFK158, that is more potent than 3PO, has improved PK
properties and causes ~80% growth inhibition in several
mouse models of human-derived tumors. We also demon-
strate that PFK158 is well tolerated in rats and dogs pro-
viding key support for a phase 1 trial in cancer patients
that will initiate in 2014. Once the MTD is established, we
intend to conduct multiple phase 1/2 trials of PFK158 in
combination with targeted agents given the ability of
PFK158 to suppress glycolysis. 50% of melanomas harbor
a BRAFV600E mutation that promotes glucose metabolism,
survival and proliferation and BRAFV600E inhibitors are
effective in ~50% of melanoma patients. Unfortunately,
resistance to these agents develops within six months and
most patients die within two years of diagnosis. Genetic
amplifications of BRAFV600E are a common cause of resis-
tance, and BRAFV600E stabilizes HIF-1a, an established
promoter of PFKFB3. We thus hypothesized that PFKFB3
may be essential for intrinsic resistance to BRAFV600E inhi-
bitors. In unpublished results, we demonstrate that 3
hours of exposure to 1 μM vemurafenib reduces HIF-1a,
PFKFB3, and F2,6BP in BRAFV600E positive A375 mela-
noma cells and that PFK158 markedly sensitizes these
cells to the apoptotic effects of vemurafenib.
Conclusions
In conclusion, PFK158 is the first PFKFB3 inhibitor to
be examined in a phase I trial and may have significant
clinical utility when combined with agents that target
driver oncogenes. Importantly, our data provide ratio-
nale for the conduct of pre-clinical studies of PFK158
combined with vemurafenib in transgenic BRAFV600E
melanoma mouse models which are in turn expected to
justify a phase 1/2 trial of the combination in
BRAFV600E-positive melanoma patients.
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